Login
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

verrica.com

What Do They Do?

Licenses cantharidin medicines for Japanese partners and sells YCANTH through wholesalers to clinics and hospitals, while developing treatments for common warts and skin cancers.

How Do They Make Money?

Verrica gets paid for YCANTH when it is delivered to wholesalers and distributors; partners pay license fees up front, milestone payments, for product and service supply, and royalties on licensed-product sales.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

43%
FY2022: 0.0%
License and collaboration revenue
57%

Who Are Their Customers?

Verrica sells YCANTH to pharmaceutical wholesalers and distributors, which supply clinics, hospitals and federal healthcare programs. Physicians obtain it through retail or specialty pharmacies or through distribution partners on a buy-and-bill basis.

Do Revenues Turn Into Profits?

No. It lost $17.9M in FY2025.

Operating income, FY2025
−34% of revenue
▲ +82% (Loss) vs FY2024 (−$65.9M, −871%)
Net income, FY2025
−50% of revenue
▲ +77% (Loss) vs FY2024 (−$76.6M, −1012%)
Free cash flow, FY2025
−50% of revenue
▲ +71% (Loss) vs FY2024 (−$61M, −806%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −52%
vs $14.3M in Q3 FY2025
Net income
▼ −4428% (Loss)
vs −$274K in Q3 FY2025
License and collaboration revenue share of revenue vs 74.9% in Q3 FY2025
  • Nov 12, 2026 Agreed to distribute YCANTH in Israel The exclusive agreement covers molluscum, and Verrica is supporting Medomie's regulatory filing in Israel.

Growing. Revenue grew 3.0x in 4 years, from $12M in FY2021 to $35.6M in FY2025, about 31% a year.

From pipeline to commercialization Earlier, the company described a pipeline spanning molluscum, external and common warts, plantar warts, and skin cancer. The latest report centers on commercializing YCANTH for molluscum and advancing common-wart and skin-cancer treatments.

Revenue over time
Product revenue, net License and collaboration revenue Collaboration
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support